Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Coadministered With Measles, Yellow Fever, and Meningitis A Vaccines in 9-Month-Old Malian Infants

Fadima C. Haidara,1 Milagritos D. Tapia,2 Samba O. Sow,1,2 Moussa Doumbia,1 Flanon Coulibaly,1 Fatoumata Diallo,1 Awa Traoré,1 Mamoudou Kodio,1 Corey L. Kelly,2 Meagan Fitzpatrick,2 Karen Kotloff,2 John C. Victor,3 and Kathleen Neuzil2

1Centre pour le Développement des Vaccins–Mali, Bamako; 2Center for Vaccine Development, University of Maryland School of Medicine, Baltimore; and 3PATH, Seattle, Washington

Background. Rotavirus vaccines given to infants are safe and efficacious. A booster dose of rotavirus vaccine could extend protection into the second year of life in low-resource countries.

Methods. We conducted an open-label, individual-randomized trial in Bamako, Mali. We assigned 600 infants aged 9–11 months to receive measles vaccine (MV), yellow fever vaccine (YFV), and meningococcal A conjugate vaccine (MenAV) with or without pentavalent rotavirus vaccine (PRV). We assessed the noninferiority (defined as a difference of ≤10%) of seroconversion and seropositivity rates to MV, YFV, and MenAV. We compared the seroresponse to PRV.

Results. Seroconversion to MV occurred in 255 of 261 PRV recipients (97.7%) and 246 of 252 control infants (97.6%; difference, 0.1% [95% confidence interval {CI}, −4.0%–4.2%]). Seroresponse to YFV occurred in 48.1% of PRV recipients (141 of 293), compared with 52.2% of controls (153 of 293; difference, −4.1% [95% CI, −12.2%–4.0%]). A 4-fold rise in meningococcus A bactericidal titer was observed in 273 of 292 PRV recipients (93.5%) and 276 of 293 controls (94.2%; difference, −0.7% [95% CI, −5.2%–3.8%]).

Rises in geometric mean concentrations of immunoglobulin A and immunoglobulin G antibodies to rotavirus were higher among PRV recipients (118 [95% CI, 91–154] and 364 [95% CI, 294–450], respectively), compared with controls (68 [95% CI, 50–92] and 153 [95% CI, 114–207], respectively).

Conclusions. PRV did not interfere with MV and MenAV; this study could not rule out interference with YFV. PRV increased serum rotavirus antibody levels.

Clinical Trials Registration. NCT02286895.

Keywords. Rotavirus vaccine; Mali; infants; booster dose; yellow fever vaccine; measles vaccine.

Rotavirus is the most common cause of severe and fatal diarrhea in young children throughout the world [1, 2]. The importance of rotavirus disease is well established in the first year of life, and studies in low-resource settings demonstrate that severe rotavirus incidence remains high through the second year of life [2, 3]. Oral rotavirus vaccines are currently recommended by the World Health Organization (WHO) Strategic Advisory Group of Experts. While rotavirus vaccines reduce severe rotavirus disease in the first year of life in low-resource settings, declines in efficacy have been reported in the second year of life [3–7].

Improving protection beyond that achieved with the current vaccination schedule could have significant global impact. One strategy to extend protection is to administer a booster dose of rotavirus vaccine at 9 months of age, concomitant with other routinely recommended Expanded Program on Immunization vaccines. In a study in Bangladesh, human monovalent rotavirus vaccine administered at 9 months of age did not interfere with immune responses to concomitantly administered vaccines and significantly increased rates of seropositivity for immunoglobulin A (IgA) and immunoglobulin G (IgG) antibodies to rotavirus [8]. Moreover, a recent model estimates that up to 20000 additional deaths could be averted with a booster dose administered at 9–12 months of age in countries with moderate and high mortality rates among children [9].

A booster dose of rotavirus vaccine had never previously been evaluated in African infants, nor were data available for the pentavalent rotavirus vaccine (PRV). In 2014, Mali introduced PRV into their routine immunization program for infants aged 6, 10, and 14 weeks. To assess the effect of concomitant administration of PRV on measles vaccine (MV) and yellow fever vaccine (YFV), we compared immune responses to these vaccines in Malian infants receiving a supplemental dose of PRV to
those observed in the absence of PRV (control group). We also measured antirotavirus immune responses within both groups. Finally, since meningococcal A conjugate vaccine (MenAV) was planned to be added to the Expanded Program on Immunization schedule at the same age, we characterized immune responses to that vaccine in the presence and absence of PRV.

METHODS

Study Design and Participants
We conducted an open-label, individual-randomized, comparative immunogenicity trial. From 15 October 2014 to 18 December 2014, participants were enrolled at 9 health centers in Bamako, Mali. Eligible infants were aged 9–11 months; resided in the study area; were generally healthy; had been fully vaccinated according to the local immunization schedule, as verified by review of the vaccination record; and had parents who were willing to follow protocol procedures. Infants were ineligible if they had history of any of the following: prior receipt of MV, YFV, or MenAV; receipt of rotavirus vaccine in the past 90 days; known hypersensitivity to any component of the study vaccines and/or following administration of previous vaccines; and any chronic medical condition or medications that might compromise the well-being of the participant, compromise compliance with study procedures, or interfere with the outcome of the study. Moderate or severe acute illness at the time of enrollment was a temporary exclusion at the discretion of the investigator.

The protocol was approved by the University of Maryland School of Medicine Institutional Review Board; the Ethical Committee of Faculté de Médecine, Pharmacie, et Odontostomatologie of Mali; the Ministry of Health of Mali; Western Institutional Review Board (Puyallup, WA); and leaders of the involved communities. Parents or guardians of participants provided informed consent prior to initiation of study procedures. The trial was registered with ClinicalTrials.gov (NCT02286895).

Procedures
All participants received MV (Serum Institute of India) by subcutaneous injection, YFV (Federal State Unitary Enterprise on Manufacture of Bacterial and Viral Preparations, Chumakov Institute of Poliomyelitis and Viral Encephalitides, Russian Academy of Medical Sciences) by intramuscular injection, and MenAV 5 μg (Serum Institute of India) by intramuscular injection at a separate site. Participants were randomly assigned at a ratio of 1:1 by a sequentially assigned numeric code to receive oral PRV (Merck) or no PRV. Placebo was not used in this study because PRV is used by the public-sector immunization program in Mali and because no placebo could be accessed. Laboratory staff performing serologic tests remained masked to individual participant group assignments.

All participants were observed for 30 minutes after vaccination. Local reactions (induration and pain) and systemic reactions (fever, lethargy, irritability, vomiting, diarrhea, loss of appetite, rash, persistent crying, and signs of potential intussusception) were assessed on days 1–5 during home visits by the trained field workers and on day 7 (±1 day) by a physician in clinic. Unsolicited adverse events (AEs) were assessed until day 28. Serious AEs were assessed from day 0 until the end of the study (day 84).

Blood samples (3–5 mL) were collected on days 0 and 28 for evaluation of antibody responses to all antigens. The anti–measles virus antibody titer was determined by a commercially available enzyme-linked IgG immunoassay (Wampole Laboratories, Princeton, NJ). Yellow fever virus–specific neutralizing antibody titers (NTs) were determined by use of the Robert Koch Institute’s standard operating procedure and with respect to international scientific references [10, 11]. A validated serum bactericidal assay (SBA) that uses baby rabbit complement was used to measure the titer of functional antibody in human sera to Neisseria meningitidis group A [12, 13]. Anti–rotavirus IgA and IgG levels were measured by an enzyme-linked immunosorbent assay at the Laboratory of Specialized Clinical Studies at the Cincinnati Children’s Hospital Medical Center (Cincinnati, OH), as described previously [14–16]. The positive control was pooled sera from subjects who had received a rotavirus vaccine or had experienced a natural rotavirus infection. The negative control was sera shown to have no antibody to rotavirus.

Outcomes
The study had 2 coprimary outcomes. First, we determined the noninferiority of the anti–measles virus IgG seroconversion rate 28 days after vaccination in the PRV group as compared to that in the group without PRV. Seroconversion was defined as seropositivity at day 28 among participants who were seronegative at baseline (defined as a titer of ≤0.90). Second, we evaluated the noninferiority of the yellow fever virus NT response in the 2 groups. A ≥4-fold response in the postvaccination yellow fever virus NT as compared to the prevaccination yellow fever virus NT, regardless of baseline serostatus, was used to define seroresponse to vaccination.

We evaluated additional evidence of PRV interference with the immune responses to MV, YFV, and MenAV by comparing the difference between PRV and control groups with regard to the following secondary outcomes: anti–measles virus IgG seroconversion rates at day 84; the yellow fever virus geometric mean titers (GMTs) at day 28; yellow fever virus seroresponse rate (defined as a ≥2-fold increase in the NT, compared with baseline) at day 28; yellow fever virus NT seroconversion rate (defined as a positive result [ie, a titer ≥1.8] among those seronegative at baseline) at day 28; SBA seroresponse rate (defined as a ≥4-fold increase in the titer, compared with baseline) at day 28; SBA GMT at day 28; and anti–rotavirus IgA and IgG seroresponse rates at day 28, restricted to those with baseline levels <20 U/mL in each group. We also conducted a superiority evaluation of the ratio of anti–rotavirus IgA and IgG geometric
mean concentrations (GMCs) in the PRV group versus the control group at day 28, first inclusive of all participants and then restricted only to subjects with baseline levels <20 U/mL. Secondary outcomes related to safety were descriptive and included the proportion of participants in each group with any of the following: immediate reactions occurring in the first 30 minutes after vaccination, solicited adverse reactions, AEs, or SAEs.

Statistical Analysis
All immunogenicity analyses and summaries were performed on a per-protocol basis (definition for each outcome are specified below). Supportive intention-to-treat analyses were conducted on all enrolled participants who received at least 1 dose of study vaccine. Safety analyses were conducted on this same intention-to-treat basis.

For the measles outcome, the per-protocol cohort included infants meeting all inclusion and no exclusion criteria, having less than seroprotective levels of measles virus IgG before vaccination, and receiving study vaccines and undergoing blood specimen collection according to schedule. Yellow fever virus–associated secondary analyses were conducted on the same per-protocol cohort, except that infants were required to have less than seroprotective anti–yellow fever virus NTs before vaccination instead of measles virus antibody.

For the MV and YFV immunogenicity primary analyses, proportions of participants reaching seroprotective levels and NTs of measles virus IgG levels and yellow fever virus, respectively, at prespecified time points after vaccination were compared between groups, using the Newcombe-Wilson method without continuity correction. A noninferiority margin of −10% was chosen as the maximal absolute reduction in proportion allowed in the group that received concomitant MV, YFV, MenAV, and PRV as compared to the group that received MV, YFV, and MenAV. Rotavirus and meningococcus A immunogenicity analyses were conducted on the per-protocol cohort without the requirement for less than seroprotective levels of measles virus or yellow fever virus IgG levels and NTs, respectively, before vaccination. Anti–rotavirus IgA and IgG GMCs and the proportion of infants who were seropositive were compared before and after vaccination in each group, using the McNemar test for correlated proportions; for GMC calculations, concentrations of <20 U/mL were converted to 10 U/mL.

We assumed 90% seroconversion and seroresponse rates in each arm for each antigen in the 2 coprimary objectives. For each coprimary outcome, to rule out a noninferiority margin of ≤10% with 95% power and a 1-sided type 1 error rate of ≤2.5%, 237 evaluable subjects were required in each group (a power of 95% was chosen to give an overall power of at least 90%). On the assumption that 79% of the cohort could be evaluated (based on a baseline seropositivity rate of 10% and a loss to follow-up of 12%), a sample size of 600 vaccinated subjects was required.

RESULTS
From 15 October 2014 to 18 December 2014, 605 infants were screened and 600 enrolled with 300 receiving PRV. All participants completed all study visits until 5 months after vaccination (Figure 1). Study follow-up was completed on 23 March 2015. The baseline characteristics among participants in both study groups were similar (Table 1).

Measles Virus
Before vaccination, 85.5% participants (87% of PRV recipients and 84% of controls) were seronegative for measles virus. Seropositivity was observed 28 days after vaccination in 255 of 261 PRV recipients (97.7%) and 246 of 252 controls (97.6%), for a difference of 0.1% (95% CI, −4.0%–4.2%) in the seroconversion rate (Table 2). On day 84, 210 of 228 PRV recipients (92.1%) who seroconverted remained seropositive, compared with 206 of 218 controls (94.5%), for a difference of −2.4% (95% CI, −7.5%–2.7%; Table 2). Similar results were obtained in the intention-to-treat population (data not shown). These results met our prespecified criteria for noninferiority of the response to MV (Figure 2).

Yellow Fever Virus
At baseline, YFV-specific immune responses were assessed in 586 participants. Increases of ≥4-fold in yellow fever virus plaque-reduction NTs occurred in 141 of 293 PRV recipients (48.1%) and 153 of 293 controls (52.2%), for a difference of −4.1% (95% CI, −12.2%–4.0%; Table 3). Because the lower bound on the CI of the difference exceeds −10, our primary criterion to establish the noninferiority of the response to YFV was not met (Figure 2). When seroresponse was defined as a ≥2-fold rise in NT, the response among PRV recipients (202 of 293 [68.9%]) was noninferior to that among controls (206 of 293 [70.3%]; difference, −1.4% [95% CI, −8.8%–6.1%]; Table 3 and Figure 2). Furthermore, seroconversion among participants who were seronegative at baseline (ie, those with a titer of <1:8) was comparable in both groups (difference, −2.3% [95% CI, −9.5%–4.8%; Table 3). Similar results were observed in the intention-to-treat population (data not shown). The GMTs were similar in both groups, and the ratio of the day 28 yellow fever virus GMT in the PRV group to that in the control group was 0.92 (95% CI, 0.77–1.09; P = .3150).

Rotavirus
Anti–rotavirus IgA and IgG seroconversion and seroresponse rates were significantly higher at day 28 among PRV recipients as compared to controls (Table 4). At baseline, 160 PRV recipients (54.8%) and 165 controls (56.5%) had IgA levels of <20 U/mL, and 91 (31.1%) and 92 (31.4%), respectively, had IgG levels of <20 U/mL. Among these IgA-seronegative participants, 91 (56.9%) in the PRV group and 52 (31.5%) in the control group had day 28 levels of ≥20 U/mL (P < .0001). Among all tested
participants, regardless of baseline status, 44.9% of PRV recipients and 27.4% of controls experienced a ≥3-fold increase in IgA titers (P < .0001), and 74.7% PRV recipients and 58.9% controls had day 28 levels of ≥20 U/mL (P < .0001). Among all tested participants, the ratio of the day 28 anti-rotavirus IgA GMC in the PRV group to that in the control group was 1.7 (95% CI, 1.2–2.4; P = .0033). Serum IgG responses were more vigorous than IgA responses, and as with IgA, responses were significantly higher among PRV recipients as compared to controls (Table 4).

**Serotype A Meningococcus**

Serum meningococcal A bactericidal responses were available for 292 PRV recipients and 293 controls. A 4-fold rise in bactericidal titer was observed in 273 PRV recipients (93.5%) and 276 controls (94.2%), with a difference of −0.7% (95% CI, −5.2%–3.8%; Table 5 and Figure 2). Postvaccination titers of ≥8 and ≥128 also met noninferiority criteria (Table 5 and Figure 2). The ratio of the day 28 SBA GMT in the PRV group to that in the control group was 0.9 (95% CI, 0.7–1.3; P = .6709).

**Safety**

There were no immediate reactions following vaccination. Systemic reactions occurred in 29 of 300 PRV recipients (9.7%) and 30 of 300 controls (10.0%) during the first 7 days of follow-up (P = 1.000). At least 1 unsolicited AE was observed through day 28 in 103 of 300 PRV recipients (34.3%) and 125 of 300 controls (41.7%; P = .0772). Of note, 39 of 300 PRV recipients (13.0%) and 51 of 300 controls (17.0%) experienced gastrointestinal illness (P = .2083) with complaints of gastroenteritis, vomiting, or diarrhea from vaccination until day 28. A total of 15 participants (7 of 300 PRV recipients [2.3%] and 8 of 300 controls [2.7%]) experienced a single SAE each over the

---

**Table 1. Baseline Characteristics of Vaccinated Participants, by Vaccines Received—Per-Protocol Population**

| Characteristic | MV, YFV, MenAV, and PRV (n = 300) | MV, YFV, and MenAV (n = 300) |
|---------------|-----------------------------------|-------------------------------|
| Age, mo       | 9.7 ± 0.7                         | 9.7 ± 0.7                    |
| Male sex      | 149 (49.7)                        | 167 (55.7)                   |
| Length, cm    | 69.5 ± 2.5                        | 69.6 ± 2.6                   |
| Weight, kg    | 8.1 ± 1.0                         | 8.2 ± 1.0                    |

Data are mean value ± SD or no. (%) of infants.

Abbreviations: MenAV, meningococcal A conjugate vaccine; MV, measles vaccine; PRV, pentavalent rotavirus vaccine; YFV, yellow fever vaccine.
3-month follow-up period \( (P = 1.000) \). These events were considered by the investigator to be unrelated to vaccination. There were no fatal SAEs, and all resolved without sequelae. There were no cases of intussusception.

**DISCUSSION**

In this first study to evaluate a booster dose of rotavirus vaccine in African infants, PRV was well tolerated and elicited robust rotavirus-specific immune responses among 9–11-month-old Malian infants. Responses to MV, YFV, and MenAV were similar regardless of whether the infant also received a booster dose of PRV. Our results met our prespecified noninferiority outcome for MV and demonstrate that PRV, when coadministered with MV, does not interfere with the immune response to MV for up to at least 3 months after vaccination. We did not meet our prespecified noninferiority criterion for YFV, as the CI for the difference between seroresponse rates in PRV and control groups was 12.5% when seroresponse was defined as a \( \geq 4 \)-fold increase in titer. This effect was not present when the secondary definition of seroresponse (ie, a \( \geq 2 \)-fold increase in titer) was used or when seroconversion was compared among those who were seronegative at baseline. Given the inclusion of MenAV into the Malian Expanded Program on Immunization schedule beginning in 2017, it is reassuring that concomitant administration of PRV did not interfere with serum bactericidal responses to that antigen.

Infants who received PRV had postvaccination increases in rotavirus-specific IgA and IgG antibody measurements that were highly statistically significant as compared to those in infants who did not receive PRV. These increases are particularly important for infants with low levels of antibody at baseline. Prior to booster vaccination, over half of participants had IgA levels of \(<20 \text{ U/mL}\), consistent with susceptibility to severe disease and indicating that vaccination could be beneficial [17].

Seroconversion rates among infants with baseline levels of \(<20 \text{ U/mL}\) were superior in the PRV group and included a nearly 2-fold increase in the IgA GMC. Of note, based on IgA measurements, 31.5% of controls and 56.9% of PRV recipients seroconverted in the month between receipt of vaccine and the follow-up visit at which blood specimens were collected. Wild-type rotavirus circulated during the study period and likely influenced these results in both groups. There were more adverse events identified as gastrointestinal illness in the control group as compared to the PRV group through 1 month after vaccination, although the difference was not statistically significant.

Our results are similar to those from a prior study of a booster dose of oral monovalent human rotavirus vaccine, conducted among 9-month-old children in Bangladesh. In that study, rotavirus vaccine was well tolerated, and the proportion of infants with a protective immune response to anti-rotavirus IgA and IgG was significantly higher among infants who received the booster [8]. As with the current study, there was no evidence of interference with MV in the Bangladesh study. While data from these booster dose studies support that administration of a PRV dose at 9 months of age could enhance and extend protection in African infants, further studies are needed to understand the long-term impact on protection against severe rotavirus disease.

| Seroconversion, Time Point | Proportion | Percentage (95% CI) | Proportion | Percentage (95% CI) | Difference, Percentage Points (95% CI) |
|---------------------------|------------|---------------------|------------|---------------------|--------------------------------------|
| MV, YFV, MenAV, and PRV   |            |                     | MV, YFV, and MenAV |            |                     |                                      |
| Day 28                    | 255/261    | 97.7 (95.9–99.5)    | 246/252    | 97.6 (95.7–99.5)    | 0.1 (–4.0–4.2)                         |
| Day 84                    | 210/228    | 92.1 (88.6–95.6)    | 206/218    | 94.5 (91.5–97.5)    | –2.4 (–7.5–2.7)                        |

Abbreviations: CI, confidence interval; MenAV, meningococcal A conjugate vaccine; MV, measles vaccine; PRV, pentavalent rotavirus vaccine; YFV, yellow fever vaccine.

*aDefined as a positive response among those who were seronegative at baseline.*

---

**Figure 2.** Noninferiority of immune responses to concomitantly administered vaccines between recipients of measles vaccine (MV), yellow fever vaccine (YFV), meningococcal A conjugate vaccine (MenAV), and pentavalent rotavirus vaccine (PRV) and recipients of MV, YFV, and MenAV—per-protocol population. The dotted line indicates no difference, and the dashed line indicates the noninferiority margin of 10%. SBT, serum bactericidal titer.
infants, a correlation between individual immune responses to rotavirus vaccines and protection from rotavirus disease has not been established. Data from clinical trials show that, on average, mean levels of anti–rotavirus IgA in a population are related to the population-level efficacy against severe disease [18, 19]. Because IgG antibodies may be maternally derived, they are generally not used in young infants to evaluate immune responses. However, as in this study, IgG titers may be useful measurements in older children and adults. Properly designed field studies of the quality required to inform policy are needed to establish the effect of a booster dose on rotavirus disease outcomes.

Initially, concerns about the association between oral rotavirus vaccines and intussusception led to age restrictions on the administration of rotavirus vaccines. The World Health Organization reviewed data on the risk and benefits of rotavirus vaccines in 2012 and concluded that the additional lives saved by removing age restrictions would far outnumber vaccine-associated intussusception morbidity and mortality [20, 21]. While this recommendation was made in the context of the primary immunization schedule, additional data may allow the same rationale to be applied to a booster dose. This study generated relevant safety data regarding use of PRV at later time points.

### Table 3. Yellow Fever Virus Serostatus and Geometric Mean Plaque-Reduction Neutralizing Titers (GMTs) in Infants, by Vaccines Received—Per-Protocol Population

| Variable | MV, YFV, MenAV, and PRV | | MV, YFV, and MenAV | | Difference, Percentage Points (95% CI) |
|----------|--------------------------|---------------------|---------------------|-----------------------------------------|
| Serologic finding | Proportion | Percentage (95% CI) | Proportion | Percentage (95% CI) | Proportion | Percentage (95% CI) |
| Seroresponse a | 141/293 | 48.1 (42.4–53.8) | 153/293 | 52.2 (46.5–57.9) | −4.1 (−12.2–4.0) |
| ≥2-fold increase | 202/293 | 68.9 (63.6–74.2) | 206/293 | 70.3 (65.1–75.5) | −1.4 (−8.8–6.1) |
| Seroconversion b | 210/287 | 73.2 (68.0–78.3) | 219/290 | 75.5 (70.6–80.5) | −2.3 (−9.5–4.8) |
| Time point | GMT (95% CI) | GMT (95% CI) | GMT Ratio (95% CI) |
| Baseline | 2.49 (2.37–2.62) | 2.40 (2.31–2.49) | … |
| Day 28 | 15.03 (13.31–16.97) | 16.82 (14.80–19.11) | 0.92* (0.77–1.09) |

Abbreviations: CI, confidence interval; MenAV, meningococcal A conjugate vaccine; MV, measles vaccine; PRV, pentavalent rotavirus vaccine; YFV, yellow fever vaccine.

aDefined as the indicated fold increase in titer from baseline to day 28.
bDefined as seropositivity (titer, ≥1:8) at day 28 among participants who were seronegative (titer, <1:8) at baseline.

### Table 4. Anti–Rotavirus Immunoglobulin A (IgA) and Immunoglobulin G (IgG) Responses in Infants, by Vaccines Received—Per-Protocol Population

| Variable | MV, YFV, MenAV, and PRV | | MV, YFV, and MenAV | | Difference, Percentage Points (95% CI) |
|----------|--------------------------|---------------------|---------------------|-----------------------------------------|
| Level | Proportion | Percentage (95% CI) | Proportion | Percentage (95% CI) | Proportion | Percentage (95% CI) |
| IgA | 131/292 | 44.9 (39.2–50.6) | 80/292 | 27.4 (22.3–32.5) | 17.5 | <.0001 |
| ≥3-fold increase from baseline to day 28 | 218/292 | 74.7 (69.7–79.6) | 172/292 | 58.9 (53.3–64.5) | 15.8 | <.0001 |
| ≥20 U/mL | 91/160 | 56.9 (49.2–64.5) | 52/165 | 31.5 (24.4–38.6) | 25.4 | <.0001 |
| IgM | 168/293 | 57.3 (51.7–63.0) | 77/293 | 26.3 (21.2–31.3) | 31.1 | <.0001 |
| ≥3-fold increase from baseline to day 28 | 275/293 | 93.9 (91.1–96.6) | 223/293 | 76.1 (71.2–81.0) | 17.7 | <.0001 |
| ≥20 U/mL | 76/91 | 83.5 (75.9–91.1) | 29/92 | 31.5 (22.0–41.0) | 52.0 | <.0001 |
| Time point | GMC (95% CI) | GMC (95% CI) | GMC Ratio (95% CI) |
| Baseline | 25.3 (19.7–32.6) | 23.7 (18.6–30.3) | … |
| Day 28 | 118.4 (90.9–154.3) | 67.9 (49.9–92.3) | 1.7 | .0033 |
| IgG | 62.5 (49.6–78.8) | 58.9 (47.1–73.7) | … |
| Day 28 | 363.6 (293.6–450.4) | 153.3 (113.8–206.5) | 2.3 | <.0001 |

Abbreviations: CI, confidence interval; GMC, geometric mean concentration; MenAV, meningococcal A conjugate vaccine; MV, measles vaccine; PRV, pentavalent rotavirus vaccine; YFV, yellow fever vaccine.
The burden of severe rotavirus gastroenteritis remains high in Mali and other resource-poor countries in the second year of life [2, 6, 7, 28]. This study of a booster dose of rotavirus vaccine, the first to be conducted in African infants, strongly supports that a PRV booster dose strategy is feasible, well tolerated, and immunogenic. While these results are compelling, global policymakers will need strong clinical evidence along with cost-effectiveness and expected impact data to recommend immunization schedule changes. In the absence of an immunological correlate of protection, efficacy studies are urgently needed to determine if an additional dose of rotavirus vaccine will be a safe and effective strategy to extend protection from the primary series into the second year of life.

**Notes**

**Acknowledgments.** We thank the participants and their families for the generous contribution of their time and effort. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

**Disclaimer.** The Bill and Melinda Gates Foundation and PATH had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

**Financial support.** This work was supported by PATH and the Bill and Melinda Gates Foundation.

**Potential conflicts of interest.** M. D. T., A. T., and K. K. receive research funds from Merck. M. F. receives research funds from the National Institutes of Health. Since the study was completed, S. O. S. has become the Mali Minister of Health. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis 2016; 62:S96–105.
2. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and etiology of diarrhoeal disease in infants and young children.

---

**Table 5. Meningococcus Serotype A Serum Bactericidal Responses in Infants, by Vaccines Received, Per-Protocol Population**

| Variable | MV, YFV, MenAV, and PRV | MV, YFV, and MenAV | Difference, Percentage Points (95% CI) |
|----------|--------------------------|-------------------|--------------------------------------|
| | Proportion | Percentage (95% CI) | Proportion | Percentage (95% CI) | Proportion | Percentage (95% CI) |
| Serologic finding | | | | | | |
| Seroresponse | 273/292 | 93.5 (90.7–96.3) | 276/293 | 94.2 (91.5–96.9) | −0.7 (−5.2–3.8) |
| Bactericidal titer | | | | | | |
| ≥8 | 282/292 | 96.6 (94.5–98.7) | 282/293 | 96.2 (94.1–98.4) | 0.3 (−3.8–4.4) |
| ≥128 | 276/292 | 94.5 (91.9–97.1) | 276/292 | 94.2 (91.5–96.9) | 0.3 (−4.1–4.8) |
| Time point | GMT (95% CI) | GMT (95% CI) | GMT Ratio (95% CI) |
| Baseline | 3.22 (2.68–3.88) | 2.81 (2.40–3.28) | ... |
| Day 28 | 2014.25 (1626.21–2494.89) | 2097.03 (1693.18–2597.20) | 0.94 (0.69–1.26) |

Abbreviations: CI, confidence interval; GMT, geometric mean titer; MenAV, meningococcal A conjugate vaccine; MV, measles vaccine; PRV, pentavalent rotavirus vaccine; YFV, yellow fever vaccine

---

aDefined as a ≥4-fold increase in titer from baseline to day 28.

bP = .6709.
in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013; 382:209–22.

3. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:615–23.

4. Isanaka S, Guindo O, Langendorf C, et al. Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger. N Engl J Med 2017; 376:1121–30.

5. Madhi SA, Kirsten M, Louw C, et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine 2012; 30:A44–51.

6. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:606–14.

7. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289–98.

8. Zaman K, Fleming JA, Victor JC, et al. Noninterference of rotavirus vaccine with measles-rubella vaccine at 9 months of age and improvements in antirotavirus immunity: a randomised trial. J Infect Dis 2016; 213:1686–93.

9. Burnett E, Lopman BA, Parashar UD. Potential for a booster dose of rotavirus vaccine to further reduce diarrhea mortality. Vaccine 2017; 35:7198–203.

10. Clarke E, Saidu Y, Adetifa JU, et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia. Lancet Glob Health 2016; 4:e534–47.

11. German Accreditation Body (DAkkS). Assay Accreditation. Vol. D-ML-13113-01-13. Frankfurt, Germany: DAkkS, 2013.

12. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27:B112–6.

13. Borrow R, Balmer P, Miller E. Meningococcal serogroups of protection–serum bactericidal antibody activity. Vaccine 2005; 23:2222–7.

14. Vesikari T, Clark HF, Offit PA, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 2006; 24:4821–9.

15. Ciarlet M, Schödel F. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq. Vaccine 2009; 27:G72–81.

16. Ward RL, Bernstein DI, Shukla R, et al. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis 1989; 159:79–88.

17. Cheuvart B, Neuzil KM, Steele AD, et al. Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: analysis of clinical trials of human rotavirus vaccine. Hum Vaccin Immunother 2014; 10:505–11.

18. Armah GE, Breiman RF, Tapia MD, et al. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine 2012; 30:A86–93.

19. Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U. A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis 2013; 208:284–94.

20. World Health Organization. Rotavirus vaccines WHO position paper. 2013; 88:49–64. http://www.who.int/wer/2013/wer8805.pdf?ua=1

21. Patel MM, Clark AD, Sanderson CF, Tate J, Parashar UD. Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis. PLoS Med 2012; 9:e1001330.

22. Djingarey MH, Diomande FV, Barry R, et al. Introduction and rollout of a new group a meningococcal conjugate vaccine (PsA-TT) in African Meningitis Belt Countries, 2010–2014. Clin Infect Dis 2015; 61:S434–41.

23. Lingani C, Bergeron-Caron C, Stuart JM, et al. Meningococcal meningitis surveillance in the African Meningitis Belt, 2004–2013. Clin Infect Dis 2015; 61:S410–5.

24. Vesikari T, Karvonen A, Borrow R, et al. Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccine. Clin Vaccine Immunol 2011; 18:878–84.

25. Kraemer MUG, Faria NR, Reiner RC Jr, et al. Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015-16: a modelling study. Lancet Infect Dis 2017; 17:330–8.

26. Roy Chowdhury P, Meier C, Laraway H, et al. Immunogenicity of yellow fever vaccine coadministered with MenAfriVac in healthy infants in Ghana and Mali. Clin Infect Dis 2015; 61:S586–93.

27. Nascimento Silva JR, Camacho LA, Siqueira MM, et al.; Collaborative Group for the Study of Yellow Fever Vaccines. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine 2011; 29:6327–34.

28. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:136–41.